National Comprehensive Cancer Network



About NCCN

NCCN Flash Update: NCCN Guidelines Updated

*Editor's Comment: The NCCN Guidelines™ for Antiemesis Version 2.2011 and Version 3.2011 were updated on January 21, 2011 and February 7, 2011 respectively. The current update is Version 3.2011.

Flash Update Sent Febuary 21, 2011

NCCN has published updates to the NCCN Guidelines for Antiemesis. These NCCN Guidelines are currently available as Version 2.2011.

Intravenous (IV) dolasetron was removed due to the FDA safety announcement regarding risk for cardiac complications; however, oral dolasetron remains in the NCCN Guidelines for Antiemesis.

 

Flash Update Sent February 7, 2011

NCCN has published updates to the NCCN Guidelines for Antiemesis. These NCCN Guidelines are currently available as Version 3.2011.

  • The algorithm for high emetic risk intravenous chemotherapy was revised to include a dose change for dexamethasone when fosaprepitant 150 mg IV is chosen as the NK-1 antagonist.
  • The discussion section of the NCCN Guidelines for Antiemesis has been updated to correspond with the treatment algorithms.

 

For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved